New achievements of pharmacology for practical medicine in prevention and therapy of acid-dependent diseases

The prevalence of GERD in most European countries and the Russian Federation is at the level of 15–20%. Hydrochloric acid plays a significant and sometimes major role in damage to the mucosa of the upper gastrointestinal tract (GIT) in patients with various acid-related diseases. Despite the presence of various classes of drugs that reduce the damaging effect of hydro-chloric acid on the mucous membrane of the upper gastrointestinal tract, acid-related diseases continues to be an urgent medical problem. The review article discusses the issues of pharmacological treatment of acid-related diseases. Such classes of drugs as antacids, H2-histamine blockers, gastroprotectors, potassium-competitive blockers of hydrochloric acid secretion are described in detail. Particular attention is paid to the group of proton pump inhibitors (PPIs). The paper evaluates the merits of each class of drugs, their significance in the treatment of acid-related diseases. One of the most popular PPIs in the Russian Federation is omeprazole. The effectiveness of the drug is determined by pharmacokinetic parameters, in particular bioavailability. The bioavailability of omeprazole of various trade names varies widely. To increase the rate and completeness of dissolution, and hence the bioavailability of poorly soluble molecules in the modern pharmaceutical industry, various disintegrants are used as excipients. The addition of sodium superdisintegrant carboxymethyl starch to the new Omez® dosage form with MiniCaps technology promotes an accelerated and more complete intake of omeprazole into the systemic circulation, helping to increase bioavailability. In addition, the innovative dosage form has a volume that is 30% smaller than the classic capsule, which improves ease of use and adherence to treatment.

1. Eusebi L.H., Ratnakumaran R., Yuan Y., Solaymani-Dodaran M., Bazzoli F., Ford A.C. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440. https://doi.org/10.1136/gutjnl-2016-313589.

2. Tack J., Talley N.J., Camilleri M., Holtmann G., Hu P., Malagelada J.R., Stanghellini V. Functional gastroduodenal disorders. Gastroenterology. 2006;130(5):1466–1479. Available at: https://www.gastrojournal.org/article/S0016-5085(06)00508-7/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F.

3. Bordin D.S., Plavnik R.G., Nevmerzhitskiy V.I., Butorova L.I., Abdulkhakov R.A., Abdulkhakov S.R. et al. Prevalence of Helicobacter pylori among medical workers in Moscow and Kazan according to ¹³С-urease breath test. Almanac of Clinical Medicine. 2018;46(1):40–49. (In Russ.) https://doi.org/10.18786/2072-0505-2018-46-1-40-49.

4. Hall J.E., Hall M.E. Medical Physiology. Elsevier; 2020. 1150 p. Available at: https://www.elsevierhealth.com.au/guyton-and-hall-textbook-of-medicalphysiology-e-book-9780323640039.html.

5. Sun D.C., Shay H. Basal gastric secretion in duodenal ulcer patients: its consideration in evaluation of gastric secretory inhibitants or stimulants. J Appl Physiol. 1957;11(2):148–154. https://doi.org/10.1152/jappl.1957.11.2.148.

6. Kukes V.G., Starodubtsev A.K. Clinical pharmacology and pharmacotherapy. Moscow: GEHOTAR-Media; 2012. 832 p. (In Russ.) Available at: https://bmfk-birsk.ru/about/book/klinfarm.pdf.

7. Zaterka S., Marion S.B., Roveda F., Perrotti M.A., Chinzon D. Historical perspective of gastroesophageal reflux disease clinical treatment. Arq Gastroenterol. 2019;56(2):202–208. https://doi.org/10.1590/S0004-2803.201900000-41.

8. Ivanova O.I., Minushkin O.N. Antacids in the modern treatment of acidbase disorders. Meditsinskiy Sovet. 2015;(13):30–37. (In Russ.) Available at: https://www.med-sovet.pro/jour/article/view/332?locale=ru_RU.

9. Salisbury B.H., Terrell J.M. Antacids. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://pubmed.ncbi.nlm.nih.gov/30252305/.

10. Meyer W. Antacids--an historical overview. Pharm Unserer Zeit. 2007;36(1):10–20. https://doi.org/10.1002/pauz.200600200.

11. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., Zayratyants O.V. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-4-70-97.

12. Simanenkov V.I., Bakulina N.V., Tikhonov S.V. Bismuth tripotassium dicitrat: from pharmaceutical characteristics to clinical efficacy. Medical Alphabet. 2019;1(6):23–28. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-6(381)-23-28.

13. Simanenkov V.I., Tikhonov S.V. Rebamipide: New opportunities of gastroenteroprotection. Terapevticheskii Arkhiv. 2015;(1)2:134–137. (In Russ.) https://doi.org/10.17116/terarkh20158712134-137.

14. Kimura T., Yoshida A., Tabuchi Y., Ikari A., Takeguchi N., Asano S. Stable expression of gastric proton pump activity at the cell surface. J Biochem. 2002;131(6):923–932. https://doi.org/10.1093/oxfordjournals.jbchem.a003183.

15. Abe K., Irie K., Nakanishi H., Suzuki H., Fujiyoshi Y. Crystal structures of the gastric proton pump. Nature. 2018;556(7700):214–218. https://doi.org/10.1038/s41586-018-0003-8.

16. Engevik A.C., Kaji I., Goldenring J.R. The Physiology of the Gastric Parietal Cell. Physiol Rev. 2020;100(2):573–602. https://doi.org/10.1152/physrev.00016.2019.

17. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD); 2012. Available at: https://www.ncbi.nlm.nih.gov/books/NBK547852.

18. Stein J., Rösch W. H2 blockers and antacids in gastrointestinal diseases. Pharm Unserer Zeit. 2007;36(1):38–43. https://doi.org/10.1002/pauz.200600203.

19. Singh Bansi D., Louis-Auguste J. Oesophagus, stomach and duodenum. In: Bennett P.N., Brown M.J., Sharma P. (eds.). Clinical Pharmacology. 11th ed. Churchill Livingstone; 2012, chapter 32. pp. 528–535. https://doi.org/10.1016/b978-0-7020-4084-9.00071-9.

20. Bordin D.S., Plotnikova E.Y., Sukhikh A.S. Treatment of acid-dependent diseases: background and topical issues. Consilium Medicum. 2013;15(8):38–44. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/93873.

21. Belmer S.V. Acid-dependent conditions: pharmacological approach to treatment. Doktor.Ru. 2004;(6):6–9. (In Russ.) Available at: https://www.gastroscan.ru/literature/authors/1881.

22. Zhang Y.S., Li Q., He B.S., Liu R., Li Z.J. Proton pump inhibitors therapy vs H2 receptor antagonists’ therapy for upper gastrointestinal bleeding after endoscopy: A meta-analysis. World J Gastroenterol. 2015;21(20):6341–6351. https://doi.org/10.3748/wjg.v21.i20.6341.

23. Mazova N.V., Marchenko A.L., Marchenko N.V. The analysis of the pharmaceutical market on the example of medicines of group of inhibitors of the proton. Drug Development and Registration. 2017;(2):272–277. (In Russ.) Available at: https://www.pharmjournal.ru/jour/article/view/441/436.

24. Oosterhuis B., Jonkman J.H. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion. 1989;44(Suppl):1:9–17. https://doi.org/10.1159/000200098.

25. Kareva E.N. Pharmacogenetic management concerning efficacy and safety of proton-pump inhibitors. RMJ. 2021;29(4):68–73. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/farmakogeneticheskoeupravlenie-effektivnostyu-i-bezopasnostyu-ingibitorov-protonnykh-pomp/.

26. Abed M.N., Alassaf F.A., Jasim M.H.M., Alfahad M., Qazzaz M.E. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole. Pharmacology. 2020;105(11–12):645–651. https://doi.org/10.1159/000506232.

27. Inatomi N., Matsukawa J., Sakurai Y., Otake K. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12–22. Available at: https://pubmed.ncbi.nlm.nih.gov/27514776/.

28. Leowattana W., Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol. 2022;28(28):3608–3619. https://doi.org/10.3748/wjg.v28.i28.3608.

29. Shaheen N.J., Falk G.W., Iyer P.G., Souza R.F., Yadlapati R.H., Sauer B.G., Wani S. Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline. Am J Gastroenterol. 2022;117(4):559–587. https://doi.org/10.14309/ajg.0000000000001680.

30. Hirano I., Chan E.S., Rank M.A., Sharaf R.N., Stollman N.H., Stukus D.R. et al. AGA Institute Clinical Guidelines Committee; Joint Task Force on AllergyImmunology Practice Parameters. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2020;124(5):416–423. https://doi.org/10.1016/j.anai.2020.03.020.

31. Kilcoyne A., O’Connor D., Ambery P. Bioavailability and bioequivalence. Pharmaceutical Medicine, Oxford Specialist Handbooks. Oxford; 2013. https://doi.org/10.1093/med/9780199609147.003.0052.

32. Alekseev K.V., Tikhonova N.V., Blinskaya Ye.V., Karbusheva Ye.U., Turchinskaya K.G., Mikheeva A.S. et al. Technology of raising the availability of biologic and pharmaceutical drugs. Journal of New Medical Technologies. 2012;19(4):43–47. (In Russ.) Available at: https://elibrary.ru/item.asp?id=18267132.

33. Smekhova I.E., Vainshtein V.A., Ladutko Y.M., Druzhininskaya O.V., Tureckova N.N. Disintegrants and their influence on the dissolution of substances of biopharmaceutical classification system classes. Drug Development and Registration. 2018;(4):62–72. (In Russ.) Available at: https://www.pharmjournal.ru/jour/article/view/634.

34. Pooresmaeil M., Namazi H. Developments on carboxymethyl starch-based smart systems as promising drug carriers: A review. Carbohydr Polym. 2021;258:117654. https://doi.org/10.1016/j.carbpol.2021.117654.